These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24843740)

  • 41. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes.
    Matthaei S; Catrinoiu D; Celiński A; Ekholm E; Cook W; Hirshberg B; Chen H; Iqbal N; Hansen L
    Diabetes Care; 2015 Nov; 38(11):2018-24. PubMed ID: 26324329
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.
    Hirose T; Suzuki M; Tsumiyama I
    Diabetes Ther; 2015 Dec; 6(4):559-571. PubMed ID: 26620049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
    Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
    Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
    Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG
    Diabetes Care; 1998 Nov; 21(11):1897-903. PubMed ID: 9802740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
    Jabbour SA; Frías JP; Hardy E; Ahmed A; Wang H; Öhman P; Guja C
    Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
    J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
    Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.
    Ji L; Lu J; Gao L; Yan X; Li J; Cheng Z; Zhang L; Tian J; Li P; Bai J; Xie D; Zhao J; Ding J; Yu Q; Wang T
    Diabetes Obes Metab; 2023 Dec; 25(12):3788-3797. PubMed ID: 37724698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
    Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial.
    Gao F; Lv X; Mo Z; Ma J; Zhang Q; Yang G; Liu W; Li Q; Zhou J; Bao Y; Jia W
    Diabetes Obes Metab; 2020 Dec; 22(12):2375-2383. PubMed ID: 32744358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study.
    Du G; Xie W; Su Y; Ma Y; Gao X; Jiang S; Liang H
    PeerJ; 2020; 8():e9905. PubMed ID: 33072435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
    Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W
    J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.